PURPOSE: The choice of an appropriate treatment option in patients with inoperable or metastatic neuroendocrine tumours (NETs) is limited, and approximately 50 % of patients have advanced NET at diagnosis, and 65 % die within 5 years. Treatment with (177)Lu-DOTATATE ((177)Lu-[DOTA(0),Tyr(3)] octreotate) is a promising new option in the treatment of metastatic NETs. METHODS: Patients with metastatic NET who underwent (177)Lu-DOTATATE during the period 2009 to 2013 were included in this retrospective study. Follow-up imaging studies including a (68)Ga-DOTANOC PET/CT scan and a posttherapy (177)Lu-DOTATATE scan were compared with baseline imaging to determine response to treatment. Progression-free survival (PFS) was calculated using the Kaplan-Meier method and Cox regression analysis was also done. RESULTS: Ten patients (25 %) had a minimal response, 13 (32.5 %) had a partial response and 9 (22.5 %) had stable disease. Progressive disease was seen in 8 patients (20 %), including 6 patients who died during or after the treatment period. The estimated mean PFS in those who received one or two cycles of (177)Lu-DOTATATE was 8.3 months (95 % CI 6.2 to 10.3 months) compared to an estimated mean PFS of 45.6 months (95 % CI 40.9 to 50.2 months) in those who received more than two cycles of (177)Lu-DOTATATE (log-rank Mantel-Cox Χ (2) = 8.01, p = 0.005). CONCLUSION: Our study showed that treatment with (177)Lu-DOTATATE should be considered in the management of NETs, considering the limited success of alternative treatment modalities. Treatment response and PFS is determined primarily by the dose delivered and best results are obtained when more than two cycles of (177)Lu-DOTATATE are given, with careful monitoring for possible side effects.
PURPOSE: The choice of an appropriate treatment option in patients with inoperable or metastatic neuroendocrine tumours (NETs) is limited, and approximately 50 % of patients have advanced NET at diagnosis, and 65 % die within 5 years. Treatment with (177)Lu-DOTATATE ((177)Lu-[DOTA(0),Tyr(3)] octreotate) is a promising new option in the treatment of metastatic NETs. METHODS:Patients with metastatic NET who underwent (177)Lu-DOTATATE during the period 2009 to 2013 were included in this retrospective study. Follow-up imaging studies including a (68)Ga-DOTANOC PET/CT scan and a posttherapy (177)Lu-DOTATATE scan were compared with baseline imaging to determine response to treatment. Progression-free survival (PFS) was calculated using the Kaplan-Meier method and Cox regression analysis was also done. RESULTS: Ten patients (25 %) had a minimal response, 13 (32.5 %) had a partial response and 9 (22.5 %) had stable disease. Progressive disease was seen in 8 patients (20 %), including 6 patients who died during or after the treatment period. The estimated mean PFS in those who received one or two cycles of (177)Lu-DOTATATE was 8.3 months (95 % CI 6.2 to 10.3 months) compared to an estimated mean PFS of 45.6 months (95 % CI 40.9 to 50.2 months) in those who received more than two cycles of (177)Lu-DOTATATE (log-rank Mantel-Cox Χ (2) = 8.01, p = 0.005). CONCLUSION: Our study showed that treatment with (177)Lu-DOTATATE should be considered in the management of NETs, considering the limited success of alternative treatment modalities. Treatment response and PFS is determined primarily by the dose delivered and best results are obtained when more than two cycles of (177)Lu-DOTATATE are given, with careful monitoring for possible side effects.
Authors: Michael Garkavij; Mattias Nickel; Katarina Sjögreen-Gleisner; Michael Ljungberg; Tomas Ohlsson; Karin Wingårdh; Sven-Erik Strand; Jan Tennvall Journal: Cancer Date: 2010-02-15 Impact factor: 6.860
Authors: Andrea Frilling; Frank Weber; Fuat Saner; Andreas Bockisch; Michael Hofmann; Jan Mueller-Brand; Christoph E Broelsch Journal: Surgery Date: 2006-12 Impact factor: 3.982
Authors: D J Kwekkeboom; W H Bakker; P P Kooij; M W Konijnenberg; A Srinivasan; J L Erion; M A Schmidt; J L Bugaj; M de Jong; E P Krenning Journal: Eur J Nucl Med Date: 2001-09
Authors: James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: Marion de Jong; Wout A P Breeman; Dik J Kwekkeboom; Roelf Valkema; Eric P Krenning Journal: Acc Chem Res Date: 2009-07-21 Impact factor: 22.384
Authors: Christina Swärd; Peter Bernhardt; Viktor Johanson; Anneli Schmitt; Håkan Ahlman; Mats Stridsberg; Eva Forssell-Aronsson; Ola Nilsson; Lars Kölby Journal: Cancer Biother Radiopharm Date: 2008-02 Impact factor: 3.099
Authors: Sanjay Gupta; James C Yao; Kamran Ahrar; Michael J Wallace; Frank A Morello; David C Madoff; Ravi Murthy; Marshall E Hicks; Jaffer A Ajani Journal: Cancer J Date: 2003 Jul-Aug Impact factor: 3.360
Authors: Giuseppe Lo Russo; Sara Pusceddu; Natalie Prinzi; Martina Imbimbo; Claudia Proto; Diego Signorelli; Milena Vitali; Monica Ganzinelli; Marco Maccauro; Roberto Buzzoni; Ettore Seregni; Filippo de Braud; Marina Chiara Garassino Journal: Tumour Biol Date: 2016-07-27
Authors: Rudolf A Werner; Christina Bluemel; Martin S Allen-Auerbach; Takahiro Higuchi; Ken Herrmann Journal: Ann Nucl Med Date: 2014-08-20 Impact factor: 2.668
Authors: Anna Sundlöv; Katarina Sjögreen-Gleisner; Johanna Svensson; Michael Ljungberg; Tomas Olsson; Peter Bernhardt; Jan Tennvall Journal: Eur J Nucl Med Mol Imaging Date: 2017-03-22 Impact factor: 9.236